137 related articles for article (PubMed ID: 18580451)
1. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
[No Abstract] [Full Text] [Related]
2. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
Däbritz J; Preston R; Hänfler J; Oettle H
Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
[No Abstract] [Full Text] [Related]
3. Early detection tools for pancreatic cancer.
Schmidt C
J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
[No Abstract] [Full Text] [Related]
4. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
[TBL] [Abstract][Full Text] [Related]
5. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer.
Marchese R; Muleti A; Brozzetti S; Gandini O; Brunetti E; French D
Br J Cancer; 2004 Jun; 90(11):2243. PubMed ID: 15150585
[No Abstract] [Full Text] [Related]
6. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis.
Liu SL; Chen G; Zhao YP; Wu WM; Zhang TP
Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):458-64. PubMed ID: 24103274
[TBL] [Abstract][Full Text] [Related]
8. Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
Gautschi O; Huegli B; Ziegler A; Gugger M; Heighway J; Ratschiller D; Mack PC; Gumerlock PH; Kung HJ; Stahel RA; Gandara DR; Betticher DC
Cancer Lett; 2007 Sep; 254(2):265-73. PubMed ID: 17449174
[TBL] [Abstract][Full Text] [Related]
9. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
10. Detection and characterization of oncogene mutations in preneoplastic and early neoplastic lesions.
Minamoto T
Methods Mol Biol; 2014; 1105():381-98. PubMed ID: 24623243
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer research matures.
Nelson NJ
J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
[No Abstract] [Full Text] [Related]
12. Portal-vein blood samples as a new diagnostic entity for pancreatic cancer.
Chapman CG; Waxman I
Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):665-7. PubMed ID: 27077275
[No Abstract] [Full Text] [Related]
13. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation analysis as a diagnostic tool.
Yan B; Chin SY; Ismail TM; Salto-Tellez M
Int J Colorectal Dis; 2011 Aug; 26(8):1083-4. PubMed ID: 21128077
[No Abstract] [Full Text] [Related]
15. Analysis of circulating tumor DNA to confirm somatic KRAS mutations.
Holdhoff M; Schmidt K; Donehower R; Diaz LA
J Natl Cancer Inst; 2009 Sep; 101(18):1284-5. PubMed ID: 19641175
[No Abstract] [Full Text] [Related]
16. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
17. Optimizing methods for the diagnosis of pancreatic cancer.
Brugge WR
J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
[No Abstract] [Full Text] [Related]
18. [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers].
Pietrasz D; Pécuchet N; Fabre E; Blons H; Chevalier L; Taly V; Laurent-Puig P; Bachet JB
Bull Cancer; 2016 Jan; 103(1):55-65. PubMed ID: 26790710
[TBL] [Abstract][Full Text] [Related]
19. Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients.
Yu S; Wu J; Xu S; Tan G; Liu B; Feng J
Cancer Biol Ther; 2012 Mar; 13(5):314-20. PubMed ID: 22310974
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
